Ideogen improving accessibility of blood cancer therapy

Based in the canton of Schwyz, the Ideogen Group will now be active across numerous different countries after taking over a Special Access Program for the prescription drug Beleodaq. The specialist in the distribution of drugs to treat rare diseases will now provide access to this drug for doctors based in Europe, North Africa, the Middle East and Russia in addition to the Commonwealth of Independent States (CIS).

The world’s only Histone Deacetylase (HDAC) Inhibitor has now been authorized for use by the US Food and Drug Administration (FDA) as part of an accelerated approval process. The drug will be used to treat patients with a rare form of blood cancer known as peripheral T-cell lymphoma (PTCL) who have suffered a relapse or whose treatment has so far proved ineffective.

Ideogen facilitates “access for patients globally affected by underserved diseases”, explains Murat Göker, Chief Commercial Officer (CCO) at the Ideogen Group, in a press release. “Our Special Access Programs allow physicians access to medicines like Beleodaq (belinostat) for special circumstances of individual patients when alternative treatment options are required”, he adds.

As Chief Operations Officer (COO) Mehmet Göker emphasizes, Beleodaq is warehoused in the EU. As such, it is available for delivery at short notice to any pharmacist or physician within continental Europe.